Skip to main content

Table 5 Univariate and multivariate analysis for event-free survival

From: The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Survival analysis

Variable

Univariate

Multivariate

HR (95 % CI)

P

HR (95 % CI)

P

Age

1.106 (0.895-1.367)

0.351

  

Tumor primary site

0.337(0.045-2.533)

0.291

  

MYCN

1.492(0.605-3.680)

0.385

  

1p

1.202(0.794-1.820)

0.384

  

11q

1.529(1.035-2.259)

0.033*

 

0.359

INSS stage

3.508(0.922-13.551)

0.066

  

COG group

4.719(1.474-15.113)

0.009*

 

0.125

NSE

1.000(1.000-1.001)

0.256

  

LDH

1.000(1.000-1.001)

0.336

  

PHOX2B

1.000(1.000-1.001)

0.212

  

BMI

6.336(1.426-28.153)

0.015*

4.677(1.032-21.205)

0.045*

SUVmean

0.981(0.644-1.493)

0.928

  

SUVmax

1.083(0.949-1.237)

0.237

  

SUVpeak

1.085(0.912-1.290)

0.358

  

MTVtotal

1.000(0.999-1.002)

0.615

  

MTV40%

1.000(0.997-1.003)

0.9

  

TLGtotal

1.000(0.999-1.001)

0.918

  

TLG40%

1.000(0.999-1.001)

0.804

  

AUC-CSHtotal

0.001(0.001-0.164)

0.007*

0.005(0.000-0.705)

0.036*

AUC-CSH40%

0.001(0.001-1.103)

0.052

  
  1. MYCN myelocytomatosis viral oncogene neuroblastoma derived homolog, INSS International Neuroblastoma Staging System, COG Children's Oncology Group, NSE neuron-specific enolase, LDH lactate dehydrogenase, PHOX2B paired-like homebox 2B, BMI bone morrow involvement, SUVmean the mean standardized uptake value, SUVmax the maximum standard uptake value, SUVpeak the peak standardized uptake value, MTV metabolic tumour volume, TLG total lesion glycolysis, AUC-CSH areas under the curve of cumulative SUV-volume histogram, HR: hazard rate, CI confidence interval, *P < 0.05